首页> 外文期刊>Journal of diabetes research. >Gene Expression Profiling of the Sciatic Nerve in Streptozotocin-Induced Diabetic Rats with Peripheral Neuropathy
【24h】

Gene Expression Profiling of the Sciatic Nerve in Streptozotocin-Induced Diabetic Rats with Peripheral Neuropathy

机译:链脲佐菌素诱导的糖尿病大鼠与外周神经病变的基因表达谱

获取原文
           

摘要

Aims. To investigate the candidate biomarkers and molecular mechanisms involved in the early phase of experimental diabetic peripheral neuropathy (DPN). Methods. Diabetes in Sprague-Dawley rats was induced with streptozotocin (STZ) treatment, followed with neurological tests and histological examinations to assess the neuropathic symptoms of DPN. Microarray was performed on the sciatic nerve tissues from control rats and DPN rats at then6th week after diabetes induction, and differentially expressed genes (DEGs) between them were identified and applied for further bioinformatic analyses. Results. Experimental DPN rats were successfully constructed, presenting significantly decreased withdrawal threshold and motor nerve conduction velocity, and typical histological changes in the sciatic nerve. 597 DEGs (186 up- and 411 downregulated) were identified in DPN rats. DEGs from the 3 most highly connected clusters in the protein-protein interaction network were enriched for biological processes or pathways such as “cell division,” “cell cycle,” “protein phosphorylation,” “chemokine signaling pathway,” “neuropeptide signaling pathway,” “response to drug,” “cellular response to insulin stimulus,” “PPAR signaling pathway,” and “glycerophospholipid metabolism.” Thirteen genes were identified as the hub DEGs in the PPI network. Eleven transcriptional factors (TFs) targeting 9 of the 13 hub DEGs were predicted. Conclusions. The present study identified a pool of candidate biomarkers such as Cdk1, C3, Mapk12, Agt, Adipoq, Cxcl2, and Mmp9 and molecular mechanisms which may be involved in the early phase of experimental DPN. The findings provide clues for exploring new strategies for the early diagnosis and treatment of DPN.
机译:目标。探讨候选生物标志物和参与实验性糖尿病外周神经病变(DPN)早期阶段的分子机制。方法。 Sprague-Dawley大鼠的糖尿病被链脲佐菌素(STZ)治疗诱导,随后具有神经检测和组织学检查,评估DPN的神经病症状。在糖尿病诱导后第6周的对照大鼠和DPN大鼠的坐骨神经组织上进行微阵列,鉴定它们之间的差异表达基因(DEG)并施加进一步的生物信息分析。结果。成功构建了实验性DPN大鼠,呈现出显着降低的取液阈值和运动神经传导速度,以及坐骨神经中的典型组织学变化。在DPN大鼠中鉴定了597℃(186次和411次下调)。来自3个最高度连接的簇蛋白 - 蛋白质相互作用网络中的群体富集为生物过程或途径,例如“细胞分裂”,“细胞周期”“蛋白质磷酸化”,“趋化因子信号通路”,“趋化学信号通路”,“神经肽信号通路”, “对药物的反应”,“对胰岛素刺激的细胞反应”,“PPAR信号通路,”和“甘油磷脂代谢”。将十三基因鉴定为PPI网络中的集线器。预测了13个集线器中的9个转录因子(TFS)靶向9。结论。本研究确定了一种候选生物标志物,例如CDK1,C3,MAPK12,AGT,AdipoQ,CXCL2和MMP9和MMP9,其可参与实验性DPN的早期阶段。调查结果提供了探索DPN早期诊断和治疗的新策略的线索。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号